EODData

MEMBERSHIP REGISTER LOG IN

FRA, 4RY: AKESO INC. O.N.

04 Nov 2025
LAST:

12.20

CHANGE:
 0.80		OPEN:
12.30		HIGH:
12.30		ASK:
0.00		VOLUME:
758
CHG(%):
6.15		PREV:
13.00		LOW:
12.20		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Nov 2512.3012.3012.2012.20758
03 Nov 2513.0013.0012.9013.00758
31 Oct 2512.4012.4012.4012.40758
30 Oct 2512.3012.3012.1012.10758
29 Oct 2512.0012.0012.0012.001.4K
28 Oct 2512.4012.4012.4012.401.4K
27 Oct 2512.6012.6012.6012.601.4K
24 Oct 2512.5012.5012.5012.501.4K
23 Oct 2512.7012.7012.5012.501.4K
22 Oct 2512.7012.8012.7012.701.4K

COMPANY PROFILE

Name:AKESO INC. O.N.
About:Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:No. 6, Shennong Road, Zhongshan, China, 528437
Website:https://www.akesobio.com
ISIN:KYG0146B1032

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:25.32 
Forward P/E:128.21 
Price to Sales:4.85 
Price to Book:1.81 
Profit Margin:-0.34 
Operating Margin:-0.35 
Return on Assets:-0.04 
Return on Equity:-0.15 
Revenue:305.93M 
Shares:897.57M 
Market Cap:10.95B 

TECHNICAL INDICATORS

MA5:12.341.1%
MA10:12.442.0%
MA20:13.127.5%
MA50:14.5319.1%
MA100:14.4618.5%
MA200:11.605.1%
STO9:20.00 
STO14:8.70 
RSI14:39.58 
WPR14:-88.89 
MTM14:-1.60
ROC14:-0.12 
ATR:0.40 
Week High:13.006.6%
Week Low:12.001.7%
Month High:15.9030.3%
Month Low:12.005.1%
Year High:19.3058.2%
Year Low:6.7580.7%
Volatility:20.89